• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过免疫荧光检测法在患者来源的卵巢癌细胞类器官中可视化 DNA 损伤修复蛋白。

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays.

机构信息

Washington University in St. Louis.

Washington University in St. Louis; University of California San Francisco.

出版信息

J Vis Exp. 2023 Feb 24(192). doi: 10.3791/64881.

DOI:10.3791/64881
PMID:36912550
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10881227/
Abstract

Immunofluorescence is one of the most widely used techniques to visualize target antigens with high sensitivity and specificity, allowing for the accurate identification and localization of proteins, glycans, and small molecules. While this technique is well-established in two-dimensional (2D) cell culture, less is known about its use in three-dimensional (3D) cell models. Ovarian cancer organoids are 3D tumor models that recapitulate tumor cell clonal heterogeneity, the tumor microenvironment, and cell-cell and cell-matrix interactions. Thus, they are superior to cell lines for the evaluation of drug sensitivity and functional biomarkers. Therefore, the ability to utilize immunofluorescence on primary ovarian cancer organoids is extremely beneficial in understanding the biology of this cancer. The current study describes the technique of immunofluorescence to detect DNA damage repair proteins in high-grade serous patient-derived ovarian cancer organoids (PDOs). After exposing the PDOs to ionizing radiation, immunofluorescence is performed on intact organoids to evaluate nuclear proteins as foci. Images are collected using z-stack imaging on confocal microscopy and analyzed using automated foci counting software. The described methods allow for the analysis of temporal and special recruitment of DNA damage repair proteins and colocalization of these proteins with cell-cycle markers.

摘要

免疫荧光是一种广泛应用于高灵敏度和特异性检测靶抗原的技术,能够准确识别和定位蛋白质、糖和小分子。虽然这项技术在二维(2D)细胞培养中已经得到很好的建立,但在三维(3D)细胞模型中的应用却知之甚少。卵巢癌类器官是 3D 肿瘤模型,能够重现肿瘤细胞克隆异质性、肿瘤微环境以及细胞-细胞和细胞-基质相互作用。因此,它们比细胞系更适合评估药物敏感性和功能生物标志物。因此,能够在原发性卵巢癌类器官上使用免疫荧光技术对于了解这种癌症的生物学特性非常有益。本研究描述了在高级别浆液性患者来源的卵巢癌类器官(PDOs)中检测 DNA 损伤修复蛋白的免疫荧光技术。在将 PDO 暴露于电离辐射后,对完整的类器官进行免疫荧光染色,以评估核蛋白作为焦点。使用共聚焦显微镜的 z 堆叠成像收集图像,并使用自动焦点计数软件进行分析。所描述的方法允许分析 DNA 损伤修复蛋白的时间和特殊募集以及这些蛋白与细胞周期标志物的共定位。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/90c6aaad3431/nihms-1959102-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/052574bab550/nihms-1959102-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/872e09926063/nihms-1959102-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/1d8f198e8d11/nihms-1959102-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/90c6aaad3431/nihms-1959102-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/052574bab550/nihms-1959102-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/872e09926063/nihms-1959102-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/1d8f198e8d11/nihms-1959102-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/10881227/90c6aaad3431/nihms-1959102-f0004.jpg

相似文献

1
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays.通过免疫荧光检测法在患者来源的卵巢癌细胞类器官中可视化 DNA 损伤修复蛋白。
J Vis Exp. 2023 Feb 24(192). doi: 10.3791/64881.
2
Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.高等级浆液性卵巢癌患者衍生类器官的生成和培养。
J Vis Exp. 2023 Jan 6(191). doi: 10.3791/64878.
3
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.预测短期患者来源卵巢癌细胞类器官中 DNA 修复抑制剂的反应。
Cancer Discov. 2018 Nov;8(11):1404-1421. doi: 10.1158/2159-8290.CD-18-0474. Epub 2018 Sep 13.
4
Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.患者来源的类器官培养在卵巢上皮性癌中的应用——技术、应用和未来展望。
Cancer Med. 2023 Oct;12(19):19714-19731. doi: 10.1002/cam4.6521. Epub 2023 Sep 30.
5
Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.在患者来源的癌细胞中筛选药物作用将类器官的反应与基因组改变联系起来。
Mol Syst Biol. 2017 Nov 27;13(11):955. doi: 10.15252/msb.20177697.
6
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.患者来源的类器官与高级别浆液性卵巢癌:从疾病建模到个体化医疗。
J Exp Clin Cancer Res. 2021 Mar 31;40(1):116. doi: 10.1186/s13046-021-01917-7.
7
High-grade serous ovarian carcinoma organoids as models of chromosomal instability.高级别浆液性卵巢癌类器官作为染色体不稳定性的模型。
Elife. 2023 May 11;12:e83867. doi: 10.7554/eLife.83867.
8
Quantification of cell death and proliferation of patient-derived ovarian cancer organoids through 3D imaging and image analysis.通过三维成像和图像分析量化患者来源的卵巢癌类器官的细胞死亡和增殖。
STAR Protoc. 2023 Dec 15;4(4):102683. doi: 10.1016/j.xpro.2023.102683. Epub 2023 Nov 16.
9
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing.卵巢癌患者衍生类器官模型在临床前药物测试中的应用。
J Vis Exp. 2023 Sep 15(199). doi: 10.3791/65068.
10
Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.从内镜活检和手术组织中开发患者来源的胃癌类器官。
Ann Surg Oncol. 2018 Sep;25(9):2767-2775. doi: 10.1245/s10434-018-6662-8. Epub 2018 Jul 12.

引用本文的文献

1
The silent spread: exploring diverse metastatic pathways in high-grade serous ovarian cancer.沉默的扩散:探索高级别浆液性卵巢癌的多种转移途径
Front Med (Lausanne). 2025 Mar 5;12:1539024. doi: 10.3389/fmed.2025.1539024. eCollection 2025.
2
A toolkit for a modern gynecologic oncology tissue bank.现代妇科肿瘤学组织库工具包。
Gynecol Oncol. 2024 Oct;189:1-8. doi: 10.1016/j.ygyno.2024.07.001. Epub 2024 Jul 5.

本文引用的文献

1
Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.高等级浆液性卵巢癌患者衍生类器官的生成和培养。
J Vis Exp. 2023 Jan 6(191). doi: 10.3791/64878.
2
Leveraging the replication stress response to optimize cancer therapy.利用复制应激反应来优化癌症治疗。
Nat Rev Cancer. 2023 Jan;23(1):6-24. doi: 10.1038/s41568-022-00518-6. Epub 2022 Nov 2.
3
Immunofluorescence staining of colorectal cancer patient-derived organoids.结直肠癌患者来源类器官的免疫荧光染色
Methods Cell Biol. 2022;171:163-171. doi: 10.1016/bs.mcb.2022.04.008. Epub 2022 Jun 6.
4
Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine.卵巢癌的三维建模:从细胞系到类器官用于发现和个性化医疗
Front Bioeng Biotechnol. 2022 Feb 10;10:836984. doi: 10.3389/fbioe.2022.836984. eCollection 2022.
5
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.GAS6/AXL 抑制通过增加 DNA 损伤和增强复制应激来提高卵巢癌对化疗和 PARP 抑制的敏感性。
Mol Cancer Res. 2022 Feb;20(2):265-279. doi: 10.1158/1541-7786.MCR-21-0302. Epub 2021 Oct 20.
6
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.复制间隙是 PARP 抑制剂与 BRCA 缺陷合成致死性的关键决定因素。
Mol Cell. 2021 Aug 5;81(15):3128-3144.e7. doi: 10.1016/j.molcel.2021.06.011. Epub 2021 Jul 2.
7
Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.探讨肿瘤微环境在铂耐药性卵巢癌中的临床价值。
Semin Cancer Biol. 2021 Dec;77:83-98. doi: 10.1016/j.semcancer.2020.12.024. Epub 2021 Jan 18.
8
Replication Gaps Underlie BRCA Deficiency and Therapy Response.复制缺口是 BRCA 缺陷和治疗反应的基础。
Cancer Res. 2021 Mar 1;81(5):1388-1397. doi: 10.1158/0008-5472.CAN-20-1602. Epub 2020 Nov 12.
9
Homologous recombination deficiency real-time clinical assays, ready or not?同源重组缺陷实时临床检测,准备好了吗?
Gynecol Oncol. 2020 Dec;159(3):877-886. doi: 10.1016/j.ygyno.2020.08.035. Epub 2020 Sep 20.
10
Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.卵巢癌中的肿瘤微环境:功能与治疗策略
Front Cell Dev Biol. 2020 Aug 11;8:758. doi: 10.3389/fcell.2020.00758. eCollection 2020.